Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Neoplasms 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Neoplasms 1NSCLC 1Lymphoma, Non-Hodgkin 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Gynecological Cancers 1Fibrosis 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1BRAF V600 Colorectal Cancer 1Anxiety Disorders 1Adenomatous Polyposis Coli 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Pharmaceutical Preparations × Clear all
NCT01973322 2025-01-09

ABSIDE

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed
34 enrolled
Dermatologic

Melanoma

NCT00203879 2013-09-05

Study of MAGE-3/Melan-A/gp 100/NA17 and rhIL-12 With/Out Low Dose IL-2 in Metastatic Melanoma

University of Chicago

Phase 2 Completed
19 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡